Gepants

Nonpeptide CGRP receptor agonists are called gepants. Gepants are a newer class of drugs, some of which have recently been approved by the FDA and EMA for the acute treatment of migraine in adults ^{[Ashina et al. 2021; EMA, 2022; FDA, 2022]}.

References:
Ashina M, Buse DC, Ashina H et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 2021; 397:1505-18.

U.S. Food & Drug Administration, Orange book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212728, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215206, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211765. Accessed Sept 2022

European Medicines Agency, Medicines. Accessed Oct 2022

Other references used on slide:
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019; 59 (1): 1–18.

Eigenbrodt, AK, Ashina H, Khan S, Diener HC, Mitsikostas D, Sinclair AJ, … & Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol 2021, 17(8): 501-514.

Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain 2017; 18 (1): 96.

Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol 2018; 14 (6): 338–350.